These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 33870183)

  • 1. Urinary Metabolomic and Proteomic Analyses in a Mouse Model of Prostatic Inflammation.
    Wei P; Hao L; Ma F; Yu Q; Buchberger AR; Lee S; Bushman W; Li L
    Urine (Amst); 2019 Jun; 1():17-23. PubMed ID: 33870183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary Amine Metabolomics Characterization with Custom 12-Plex Isobaric DiLeu Labeling.
    Wei P; Hao L; Thomas S; Buchberger AR; Steinke L; Marker PC; Ricke WA; Li L
    J Am Soc Mass Spectrom; 2020 Sep; 31(9):1854-1860. PubMed ID: 32678615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative proteomic analysis of a genetically induced prostate inflammation mouse model via custom 4-plex DiLeu isobaric labeling.
    Hao L; Thomas S; Greer T; Vezina CM; Bajpai S; Ashok A; De Marzo AM; Bieberich CJ; Li L; Ricke WA
    Am J Physiol Renal Physiol; 2019 Jun; 316(6):F1236-F1243. PubMed ID: 30995113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive urinary metabolomic characterization of a genetically induced mouse model of prostatic inflammation.
    Hao L; Shi Y; Thomas S; Vezina CM; Bajpai S; Ashok A; Bieberich CJ; Ricke WA; Li L
    Int J Mass Spectrom; 2018 Nov; 434():185-192. PubMed ID: 30872949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Custom 4-Plex DiLeu Isobaric Labels Enable Relative Quantification of Urinary Proteins in Men with Lower Urinary Tract Symptoms (LUTS).
    Greer T; Hao L; Nechyporenko A; Lee S; Vezina CM; Ricke WA; Marker PC; Bjorling DE; Bushman W; Li L
    PLoS One; 2015; 10(8):e0135415. PubMed ID: 26267142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Proteomics Approach to Identify Serum and Urinary Biomarkers and Pathways that Associate with Lower Urinary Tract Symptoms in Men and Women: Pilot Results of the Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) Study.
    Helfand BT; Andreev VP; Siddiqui NY; Liu G; Erickson BA; Helmuth ME; Lutgendorf SK; Lai HH; Kirkali Z;
    Urology; 2019 Jul; 129():35-42. PubMed ID: 30922973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-Depth Characterization and Validation of Human Urine Metabolomes Reveal Novel Metabolic Signatures of Lower Urinary Tract Symptoms.
    Hao L; Greer T; Page D; Shi Y; Vezina CM; Macoska JA; Marker PC; Bjorling DE; Bushman W; Ricke WA; Li L
    Sci Rep; 2016 Aug; 6():30869. PubMed ID: 27502322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does Inflammation Mediate the Obesity and BPH Relationship? An Epidemiologic Analysis of Body Composition and Inflammatory Markers in Blood, Urine, and Prostate Tissue, and the Relationship with Prostate Enlargement and Lower Urinary Tract Symptoms.
    Fowke JH; Koyama T; Fadare O; Clark PE
    PLoS One; 2016; 11(6):e0156918. PubMed ID: 27336586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative quantification of amine-containing metabolites using isobaric N,N-dimethyl leucine (DiLeu) reagents via LC-ESI-MS/MS and CE-ESI-MS/MS.
    Hao L; Zhong X; Greer T; Ye H; Li L
    Analyst; 2015 Jan; 140(2):467-75. PubMed ID: 25429371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the "gene-protein-metabolite" network of coronary heart disease with phlegm and blood stasis syndrome by integrated multi-omics strategy.
    Yang G; Zhou S; He H; Shen Z; Liu Y; Hu J; Wang J
    Front Pharmacol; 2022; 13():1022627. PubMed ID: 36523490
    [No Abstract]   [Full Text] [Related]  

  • 11. Development of isotope labeling liquid chromatography mass spectrometry for mouse urine metabolomics: quantitative metabolomic study of transgenic mice related to Alzheimer's disease.
    Peng J; Guo K; Xia J; Zhou J; Yang J; Westaway D; Wishart DS; Li L
    J Proteome Res; 2014 Oct; 13(10):4457-69. PubMed ID: 25164377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unveiling prostatic inflammation to optimize management of lower urinary tract symptoms: a discussion with experts.
    Gacci M; Nunzio C; Gravas S
    Biomark Med; 2023 Sep; 17(18):739-745. PubMed ID: 37970796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated tissue proteome and metabolome reveal key elements and regulatory pathways in cutaneous squamous cell carcinoma.
    Chen W; Rao J; Liu Z; You X; Yuan F; Le F; Tang M; Zhou M; Xie T
    J Proteomics; 2021 Sep; 247():104320. PubMed ID: 34237460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mass spectrometric based approaches in urine metabolomics and biomarker discovery.
    Khamis MM; Adamko DJ; El-Aneed A
    Mass Spectrom Rev; 2017 Mar; 36(2):115-134. PubMed ID: 25881008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms: What Is the Role and Significance of Inflammation?
    Lloyd GL; Marks JM; Ricke WA
    Curr Urol Rep; 2019 Aug; 20(9):54. PubMed ID: 31377881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urodynamics tests for the diagnosis and management of bladder outlet obstruction in men: the UPSTREAM non-inferiority RCT.
    Lewis AL; Young GJ; Selman LE; Rice C; Clement C; Ochieng CA; Abrams P; Blair PS; Chapple C; Glazener CM; Horwood J; McGrath JS; Noble S; Taylor GT; Lane JA; Drake MJ
    Health Technol Assess; 2020 Sep; 24(42):1-122. PubMed ID: 32902375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia.
    De Nunzio C; Salonia A; Gacci M; Ficarra V
    World J Urol; 2020 Nov; 38(11):2771-2779. PubMed ID: 32060633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary and Plasma Metabolomics Identify the Distinct Metabolic Profile of Disease State in Chronic Mouse Model of Multiple Sclerosis.
    Singh J; Cerghet M; Poisson LM; Datta I; Labuzek K; Suhail H; Rattan R; Giri S
    J Neuroimmune Pharmacol; 2019 Jun; 14(2):241-250. PubMed ID: 30315511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
    Gacci M; Andersson KE; Chapple C; Maggi M; Mirone V; Oelke M; Porst H; Roehrborn C; Stief C; Giuliano F
    Eur Urol; 2016 Jul; 70(1):124-133. PubMed ID: 26806655
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.